Molecular Mechanisms of Vascular Relaxation

血管舒张的分子机制

• 批准号: 6812078
• 负责人: MICHAEL E MENDELSOHN
• 金额: $ 222.07万
• 依托单位: TUFTS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-08-02 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6812078
• 关键词: blood pressure; clinical research; genetic regulation; hypertension; muscle contraction; muscle relaxation; protein structure function; vascular smooth muscle; vasodilation; vasomotion

DESCRIPTION (provided by applicant): Many cardiovascular diseases are characterized by disordered vascular function. Abnormalities in vascular smooth muscle cell (VSMC) tone are important in the pathogenesis of hypertension and atherosclerosis, but are not well understood. The long-term objective of this PPG is to understand the complex underlying molecular mechanisms that regulate vascular tone in health and disease. The fundamental hypothesis that will be tested is that loss of the normal function of the critical proteins that regulate vascular smooth muscle cell contraction and relaxation directly causes abnormal vasomotion and disorders of blood pressure regulation. The program we propose takes advantage of an extensive and well-developed infrastructure and ongoing collaborations between the Tufts-New England Medical Center Molecular Cardiology research Institute (MCRI), its NHLBI SCOR in Ischemic Heart Disease, the Framingham Heart Study, and the Housman Genomics Laboratory at MIT. Four projects are proposed: P1: "Genetics of Vasorelaxation and Cardiovascular Responses"; P2: "Mechanisms of PKG-mediated Vascular Relaxation"; P3: "BKca Channel Regulation by PKG in Vascular Smooth Muscle"; and P4: "Vascular Dysfunction as an Etiology of Hypertension" in Mouse Models. Three Cores are also proposed (Genomics; Mouse; Administrative). The VSMC proteins that are the specific focus of this proposal include three proteins that we show are essential for normal blood pressure: RGS2, the regulator of Gq-protein signaling; estrogen receptor a; and the BKca potassium channel (a and a subunits), as well as the two physiologically most relevant myosin phosphatase regulatory kinases, Rho Kinase (ROCK) and PKGIa, the effector of nitric oxide/cGMO. Genetically altered mice for PKGI, RGS2, ERa and the BKca channel all demonstrate vascular contractile abnormalities and hypertension. This PPG provides extensive preliminary data from human genomic studies, intact mice, mouse vascular rings, cultured human and mouse vascular cells, patch-clamping, signal transduction experiments, and detailed renal physiology. The ability of the assembled investigators to collaborate effectively is demonstrated throughout the proposal. An important corollary of the hypothesis to be tested is the concept that hypertension can arise from primary abnormalities of the VSMC proteins that regulate vascular relaxation. To formally test this hypothesis, targeted mutations in these critical VSMC regulatory genes are introduced into mice and sought in humans. The highly integrated studies of this PPG are likely to lead to new diagnostic and therapeutic approaches to hypertension and related cardiovascular diseases.

描述（由申请人提供）： 许多心血管疾病的特征是血管功能紊乱。 血管平滑肌细胞（VSMC）张力异常在高血压和动脉粥样硬化的发病机制中具有重要意义，但目前尚不清楚。 PPG的长期目标是了解在健康和疾病中调节血管张力的复杂潜在分子机制。 将要检验的基本假设是，调节血管平滑肌细胞收缩和舒张的关键蛋白质的正常功能的丧失直接导致异常血管运动和血压调节障碍。 我们提出的计划利用了塔夫茨-新英格兰医学中心分子心脏病研究所（MCRI），其缺血性心脏病NHLBI SCOR，心脏病研究和麻省理工学院Housman基因组学实验室之间广泛而发达的基础设施和持续的合作。 建议开展四个项目：第一名：P2：“PKG介导的血管舒张机制”; P3：“血管平滑肌中PKG对BKca通道的调节”; P4：“血管功能障碍作为高血压的病因”。 还提出了三个核心（基因组学;小鼠;管理）。 VSMC蛋白是该提案的具体焦点，包括我们显示对正常血压至关重要的三种蛋白质：RGS 2，Gq蛋白信号传导的调节剂;雌激素受体a;和BKca钾通道（a和a亚基），以及两种生理上最相关的肌球蛋白磷酸酶调节激酶，Rho激酶（ROCK）和PKGIa，一氧化氮/cGMO的效应子。 PKGI、RGS 2、ER α和BKca通道的基因改变的小鼠都表现出血管收缩异常和高血压。 该PPG提供了来自人类基因组研究、完整小鼠、小鼠血管环、培养的人类和小鼠血管细胞、膜片钳、信号转导实验和详细的肾脏生理学的广泛初步数据。 在整个提案中，都证明了集合起来的调查人员进行有效合作的能力。 有待检验的假设的一个重要推论是，高血压可由调节血管舒张的VSMC蛋白的原发性异常引起。 为了正式验证这一假设，将这些关键VSMC调控基因中的靶向突变引入小鼠并在人类中寻找。 PPG的高度整合研究可能会导致高血压和相关心血管疾病的新的诊断和治疗方法。